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OBJECTIVE—To identify physiological and clinical variables
associated with development of type 2 diabetes up to 12 years
after pregnancies complicated by gestational diabetes.
RESEARCH DESIGN AND METHODS—Seventy-two islet cell
antibody–negative nondiabetic Hispanic women had oral (oGTT)
and intravenous (ivGTT) glucose tolerance tests, glucose clamps,
and body composition assessed between 15 and 30 months after
pregnancies complicated by gestational diabetes mellitus (GDM).
They returned for oGTTs at 15-month intervals until they
dropped out, developed diabetes, or reached 12 years postpar-
tum. Cox regression analysis was used to identify baseline
predictors and changes during follow-up that were associated
with development of type 2 diabetes.
RESULTS—At baseline, relatively low insulin sensitivity, insulin
response, and -cell compensation for insulin resistance were
independently associated with development of diabetes. During
follow-up, weight and fat gain and rates of decline in -cell
compensation were signiﬁcantly associated with diabetes, while
additional pregnancy and use of progestin-only contraception
were marginally associated with diabetes risk.
CONCLUSIONS—In Hispanic women, GDM represents detec-
tion of a chronic disease process characterized by falling -cell
compensation for chronic insulin resistance. Women who are
farthest along at diagnosis and/or deteriorating most rapidly are
most likely to develop type 2 diabetes within 12 years after the
index pregnancy. Weight gain, additional pregnancy, and proges-
tin-only contraception are potential modiﬁable factors that in-
crease diabetes risk. Diabetes 59:2625–2630, 2010
T
he diagnosis of gestational diabetes mellitus
(GDM) identiﬁes relatively young women with-
out known diabetes who have circulating glu-
cose concentrations in the upper end of the
population distribution during pregnancy. Those women
have a 20–60% risk of developing diabetes, especially type
2 diabetes, in the 5–10 years after the index pregnancy (1).
Thus, they provide an opportunity to study diabetes in
evolution to determine what clinical and physiological
factors predict and/or attend the development of diabetes.
Cross-sectional studies of glucose regulation conducted
during and after pregnancy (2–4) indicate that women
with GDM have, on average, more insulin resistance and
less pancreatic -cell compensation for that resistance
than to women who maintain normal glucose levels in
pregnancy. Longitudinal studies are relatively few in num-
ber and limited to relatively short times after the index
pregnancy. For example, our group has reported that, in
Hispanic women, -cell compensation for chronic insulin
resistance falls progressively during the ﬁrst 5 years after
the index pregnancy (5).
Glucose levels rise quite slowly until compensation
reaches low levels (e.g., 15% of normal for acute insulin
secretion), at which time glucose may rise very quickly
and into the diabetic range as -cell compensation falls
further. Predictors of diabetes in this context could reﬂect
the greatest degree of deterioration at baseline testing
and/or the greatest rate of deterioration thereafter. In the
present report, we examine the relative contribution of
such factors during what we believe to be the longest
detailed study of glucose regulation following pregnancies
complicated by GDM.
RESEARCH DESIGN AND METHODS
Subjects were islet cell antibody–negative women who participated in a
longitudinal study of the pathogenesis of type 2 diabetes following GDM.
Selection of the original cohort has been described in detail (6). Brieﬂy, all
Latino women referred to Los Angeles County Women’s Hospital for manage-
ment of GDM between August 1993 and March 1995 were asked to participate
if they met all of the following criteria: 1) gestational age between 28 and 34
weeks, 2) no current or prior insulin therapy, 3) all fasting serum glucose
concentrations 130 mg/dl (7.2 mmol/l) during pregnancy, 4) otherwise
uncomplicated singleton pregnancy, and 5) both parents and at least three of
four grandparents were from Mexico, Guatemala, or El Salvador. All women
had detailed metabolic testing during the third trimester (6). They were asked
to return for a 75-g oral glucose tolerance test (oGTT) 6 months postpartum
and then for an oGTT, intravenous glucose tolerance test (ivGTT), and glucose
clamp at 15 months postpartum. oGTTs and ivGTTs were scheduled every
15 months thereafter. Height, weight, and information on contraceptive use
and pregnancies were collected at each visit. Bioelectrical impedance was
measured at each oGTT visit to assess body composition. At the time of
diagnosis of impaired glucose tolerance or diabetes, subjects met with a
dietitian and received advice on nutrition and daily walking. Subjects re-
mained in follow-up until they withdrew consent, were lost to follow-up,
developed a fasting plasma glucose concentration 140 mg/dl, or reached the
ﬁnal scheduled study visit 12 years postpartum. Women who were pregnant at
the time of a scheduled battery of tests were studied at least 4 months after
pregnancy and at least 1 month after completion of breastfeeding.
All subjects gave written, informed consent for participation in the study,
which was approved by the institutional review board of the University of
Southern California and the Los Angeles County and the University of
Southern California Medical Center.
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physiological changes associated with development of diabetes from the ﬁrst
postpartum visit onward, we analyzed data from all subjects who 1) had
baseline oGTT, ivGTT, glucose clamp, and body composition studies without
diabetes within 30 months postpartum and 2) returned for at least one
additional oGTT to determine diabetes status. Follow-up data were used up to
earlier of either the diagnosis of diabetes by American Diabetes Association
criteria (fasting 126 mg/dl or 2 h 200 mg/dl) or the last visit without
diabetes.
Testing protocols. For the baseline battery of oGTT, ivGTT, glucose clamp,
and body composition, subjects came to the general clinical research center
on 3 separate days, at least 48 h apart, after 8–12 h overnight fasts and at least
3 days on an unrestricted diet. The order of ivGTTs and clamps was alternated
among individuals.
On one day, bioelectrical impedance (BIA) was measured immediately
prior to an oGTT. For BIA, subjects lay supine while plastic electrodes were
placed on their right hand and foot and a trained technician took dual
resistance and reactance readings with a Quantom Impedance Meter (RJL
Systems, Clinton Township, MI). For oGTTs, subjects drank 75 g of dextrose.
Blood was obtained from an antecubital venous catheter before and 15, 30, 60,
90, 120, and 180 min after the glucose ingestion, placed on ice, and plasma was
separated within 20 min and stored at 80°C.
On a separate day, an ivGTT was performed starting between 0700 and
1000 h. Dextrose (300 mg/kg) was injected over 1 min, followed in 20 min by
a 5-min infusion of crystalline human insulin (0.03 units/kg). Arterialized
venous blood was drawn into iced tubes before (n  2) and for 240 min after
(n  32) the dextrose injection. Plasma was separated within 20 min and
stored at 80°C.
On a third day, a glucose clamp was performed starting between 0600 and
0630 h. A primed (0.035 mmol/kg body wt), continuous (2.5  10
4 mmol/
min/kg) infusion of 6,6
2H2 D-glucose (“tracer”) was administered through an
antecubital vein for 360 min. A nonprimed infusion of crystalline human
insulin (40 mU/min per m
2 body surface area) was administered during the
ﬁnal 180 min of the tracer infusion. Dextrose (20% wt/vol in water), containing
dideutero-glucose (0.021 mmol/cc) to minimize changes in plasma tracer
enrichment, was given to maintain arterialized venous plasma glucose con-
centrations at 88 mg/dl during the insulin infusion. Blood samples for
measurement of tracer, hormone/ and metabolite concentrations were drawn
into ice-cold tubes at 90, 50, 30, 10, 30, 60, 90, 120, 160, and 180 min
relative to the start of the insulin infusion. Plasma was separated within 20
min and stored at 80°C.
Laboratory analysis. Glucose was measured by glucose oxidase (Beckman
Glucose Analyzer II; Beckman, Brea, CA). Insulin was measured by a
radioimmunoassay (Novo Pharmaceuticals, Danbury, CT) that measured
insulin and proinsulin. Plasma free fatty acids (FFAs) were measured by an
enzymatic colorimetric method (WAKO Chemicals, Richmond, VA). Plasma
adiponectin and leptin levels were measured using radioimmunoassay kits
from Linco Research. Plasma C-reactive protein (CRP) and interleukin (IL)-6
were measured using CRP enzyme-linked immunosorbent assays and ultra-
sensitive IL-6 enzyme-linked immunosorbent assays kits from ALPCO Diag-
nostics. 6,6,
2H2-glucose concentrations in infusates and perchloroacetate
(PCA) supernatants of plasma were measured by gas chromatography and
mass spectrometry after conversion of glucose to its aldonitrile penta-acetate
derivative. Anti–pancreatic islet cell antibodies in plasma were measured in
the laboratory of Dr. Jerry Palmer by an indirect immunoﬂuorescence assay
using human pancreas.
Data analysis. BMI was calculated as weight in kilograms divided by the
square of height in meters. Diabetes was diagnosed by oGTTs using the
American Diabetes Association criteria (7). ivGTT results were analyzed using
the MINMOD program (8) to obtain measures of fractional glucose disappear-
ance due to an increase in insulin above basal (insulin sensitivity; SI). The
acute insulin response to intravenous glucose (AIRg) was calculated by the
trapezoid rule as the incremental area under the insulin curve during the ﬁrst
10 min after the glucose injection. The product of SI and AIRg (the disposition
index; DI) was calculated as a measure of acute pancreatic -cell compensa-
tion for insulin resistance (8). Body fat and fat-free mass were calculated by
the formula of Kotler et al. (9) using height, weight, and bioelectrical
impedance analysis measurements.
Follow-up data were used up to the diagnosis of diabetes or the last visit
without diabetes, whichever occurred ﬁrst. Cumulative diabetes incidence
rates were estimated using life-table methodology and displayed using Kaplan-
Meier plots. Cox proportional hazard regression was used to test for associ-
ations between baseline and/or follow-up variables and time to diabetes
development. Baseline variables were treated as ﬁxed covariates and fol-
low-up variables were treated as time-dependent covariates. The baseline
measures included all variables listed in Table 1. Follow-up measures included
changes from baseline in body weight and fat and disposition index, the
presence or absence of additional pregnancies, and use of hormonal contra-
ception. The proportional hazard assumption was evaluated by testing for
interaction between the covariate and time in the model; no signiﬁcant
violation was found for the tested variables.
All statistical tests were two-sided, and statistical signiﬁcance was deﬁned
as P  0.05.
RESULTS
Baseline characteristics. A total of 72 women met the
inclusion criteria for this report. Sixty women had their
baseline visits at 15 months postpartum and 12 had their
baseline visits at 30 months. At baseline, 26 women had
TABLE 1
Baseline characteristics
Variable
Median (interquartile
range)
Age (years) 32.2 (28.2–36.4)
BMI (kg/m
2) 30.7 (27.8–32.8)
Systolic blood pressure (mmHg) 111 (104–119)
Diastolic blood pressure (mmHg) 69 (64–74)
Body percent fat (%)* 44.0 (40.7–48.4)
Fasting total cholesterol (mg/dl) 169 (155–202)
Fasting HDL cholesterol (mg/dl) 38 (32–44)
Fasting LDL cholesterol (mg/dl) 110 (93–129)
Fasting triglycerides (mg/dl) 127 (82–170)
Fasting free fatty acid (mol/l) 468 (382–570)
Fasting adiponectin (ng/ml) 6,034 (4,584–7,362)
Fasting CRP (ng/ml) 28.9 (14.2–57.3)
Fasting leptin (ng/ml) 11.3 (8.7–13.7)
Fasting IL-6 (pg/ml) 2.4 (1.5–3.2)
oGTT†
Fasting glucose (mg/dl) 95.0 (90.5–104)
2-h glucose (mg/dl) 142.5 (119.5–166)
Glucose total area
(AUC: mg/dl per min/1,000) 25.0 (22.4–28.6)
Fasting insulin (U/ml) 17.5 (12.5–25)
2-h insulin (U/ml) 110 (77–178)
Insulin total area
(U/ml per min/1,000) 18.1 (13.2–25.3)
30 	insulin (U/ml)‡ 80.5 (54.5–110)
ivGTT
Insulin sensitivity
(SI; min/U/ml  10
4)§ 1.27 (0.95–2.0)
Acute insulin response
(AIRg, U/ml  min) 509 (304–843)
Disposition index (DI: SI  AIRg)¶ 834 (423–1,320)
Hyperinsulinemic-euglycemic clamp**
Basal glucose production
(HGO: mmol/min/m
2) 0.38 (0.33–0.42)
Basal glucose clearance
(Clrglu: 100  ml/min/m
2) 7.11 (6.43–7.79)
Steady-state glucose infusion rate
(Ginf:mmol/min/m
2) 0.70 (0.57–0.79)
Steady-state 	HGO (mmol/min/m
2)†† 0.27 (0.23 to 0.30)
Steady-state 	Clrglu
(100  ml/min/m
2)†† 10.1 (7.6–12.9)
To convert the glucose in unit of mg/dl to the SI unit of mmol/l,
multiply the number in the table by 0.0555. *Estimated by bioelec-
trical impedance. †During 75-g oGTTs. ‡Calculated as 30 min insu-
lin  fasting insulin during oGTT. §Calculated by minimal model
analysis of ivGTT insulin and glucose data. Incremental insulin area
during ﬁrst 10 min of ivGTT. ¶A measure of -cell compensation for
insulin resistance. **Basal values are the means of data collected
during the last 90 min of the 3-h basal tracer infusion period, and
steady-state values are the means of data collected during the ﬁnal 30
min of the 3-h euglycemic insulin infusion period. ††Calculated as
steady state-basal.
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impaired 2-h glucose alone, and 19 had impaired fasting
and 2-h glucose levels using American Diabetes Associa-
tion criteria (7). Baseline characteristics are summarized
in Table 1.
Follow-up. The average annual rate of loss to follow-up
was 6.5%. During a median follow-up of 72 months (mini-
mum 12 months; maximum 142 months), 31 (43%) of the
women developed type 2 diabetes. The average annual
incidence rate of diabetes, calculated by person-years, was
7.2%. The annual diabetes incidence rates were 4.1, 6.9, 7.0,
and 14.8% in women whose oGTT values at baseline were,
respectively, normal, impaired fasting alone, impaired 2-h
alone, and impaired fasting and 2-h glucose together. The
Kaplan-Meier plot of diabetes cumulative incidence rates
appears in Fig. 1.
Weight and glucose increased signiﬁcantly during fol-
low-up, while acute insulin secretion (AIRg) and the dis-
position index (DI) fell signiﬁcantly (Table 2). Twenty
women experienced a total of 23 pregnancies. Nine
women used combination oral contraceptives exclusively
for a median of 21 months (range 2–67). Eight women
used progestin-only contraception exclusively for a me-
dian of 15 months (3–40). One woman started with a
progestin-only contraceptive, was off from any hormonal
contraception, and then switched to combination oral
contraceptives.
Factors associated with development of diabetes.
Univariate Cox regression analysis using each of the
baseline variables presented in Table 1 revealed that
relatively high glucose, relatively low insulin sensitivity,
relatively low insulin responses, and relatively low -cell
compensation for insulin resistance were associated with
development of diabetes (Table 3). Multivariate Cox re-
gression analysis using all baseline variables revealed four
that were signiﬁcantly associated with development of
diabetes (Table 4). The strongest was -cell compensation
for insulin resistance, expressed as the disposition index
from ivGTTs. Women with the lowest disposition index
had the highest risk of developing diabetes. The other
baseline predictors identiﬁed from multivariate analysis
were insulin sensitivity, measured as incremental glucose
clearance during hyperinsulinemic clamps (low  in-
creased risk), total glucose area during oGTTs (high 
increased risk), and the 30-min increment in insulin on
oGTTs (low  increased risk).
Once the effects of these baseline variables were con-
sidered, three clinical variables assessed during follow-up
provided additional and independent information about
the risk of diabetes (Table 5; baseline and follow-up
variables in ﬁnal multivariate-adjusted model). Weight
change (gain  increased risk, adjusted P  0.021) was
signiﬁcantly associated with diabetes risk. Change in body
fat, assessed by bioelectrical impedance, gave results that
were very similar to change in body weight (hazard ratio
[HR] 1.68, adjusted P  0.04). Additional pregnancy (in-
creased risk, adjusted P  0.085) and use of progesterone-
only contraception (increased risk versus other hormonal
and nonhormonal forms, adjusted P  0.068) were mar-
ginally associated with diabetes risk despite the limited
statistical power associated with the infrequency of these
events.
We also examined change from baseline in -cell
compensation (DI) from ivGTTs for association with
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FIG. 1. Kaplan-Meier plot of diabetes cumulative incidence rate in 72
women without diabetes at entry and with at least one follow-up oGTT.
Vertical lines are 95% CIs. The numbers given by the Subjects line
included subjects who developed diabetes and who were under fol-
low-up without diabetes by the corresponding follow-up years.
TABLE 2
Rates of change during follow-up*
Variables Median (interquartile range)
Weight (kg/year) 0.69 (0.18–1.25)†
Fasting glucose (mg/dl/year) 1.3 (0.3–3.4)†
oGTT 2-h glucose (mg/dl/year) 4.6 (1.7–12.9)†
ivGTT SI (unit/year) 0.0 (0.12 to 0.08)
ivGTT AIRg (unit/year) 24.3 (72.8 to 0.0)†
ivGTT DI (unit/year) 41.6 (106 to 0.0)†
To convert the glucose in unit of mg/dl to the SI unit of mmol/l,
multiply the number in the table by 0.0555. *Variables are deﬁned in
Table 1. †P  0.0001 vs. zero using random coefﬁcient mixed-effects
regression models. SI, AIRg, and DI were log transformed for
statistical testing.
TABLE 3
Univariate signiﬁcant baseline predictors of diabetes
Variables* HR (95% CI)† P value
Glucose
oGTT fasting 1.49 (1.03–2.17) 0.03
oGTT 2-h 1.82 (1.24–2.67) 0.002
oGTT total area 2.23 (1.52–3.27) 0.0001
Insulin sensitivity
ivGTT SI‡ 0.61 (0.38–0.99) 0.047
Clamp Ginf‡ 0.53 (0.36–0.77) 0.001
Clamp 	Clrglu 0.50 (0.32–0.77) 0.002
-Cell function
ivGTT AIRg‡ 0.38 (0.24–0.61) 0.0001
ivGTT DI‡ 0.27 (0.16–0.46) 0.0001
*Variables and units are deﬁned in Table 1. †By Cox regression,
expressed as per 1-SD unit increase. ‡Variables were log trans-
formed; SDs were calculated using log-transformed data.
TABLE 4
Multivariate signiﬁcant baseline predictors of diabetes*
Variables† Adjusted HR‡ 95% CI Adjusted P value
ivGTT DI§ 0.41 (0.24–0.71) 0.001
Clamp 	Clrglu 0.50 (0.29–0.84) 0.01
oGTT total area 1.68 (1.05–2.66) 0.028
oGTT 30 	insulin§ 0.60 (0.38–0.96) 0.034
*P  0.05 on multivariate Cox regression analysis considering all
baseline variables listed in Table 1. †Variables and units are deﬁned
in Table 1. ‡By Cox regression adjusting for other variables in the
table, expressed per 1-SD unit increase. §Variables were log trans-
formed; SDs were calculated using log-transformed data.
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on the log scale was signiﬁcantly associated with diabe-
tes development (HR 0.73 [95% CI 0.61–0.88], P 
0.001). Adjustment for baseline disposition index de-
creased the level of association, but the association
remained statistically signiﬁcant (adjusted HR 0.83 [95%
CI 0.69–0.99], P  0.045). Thus, the rate of decline in
disposition index had an impact on diabetes risk beyond
the risk associated with low disposition index at base-
line. Further adjustment for the other three signiﬁcant
baseline variables had almost no impact on the relative
hazard estimate for change in disposition index. Adjust-
ment for weight change during follow-up reduced the
HR to 0.94 (95% CI 0.77–1.14, P  0.51).
The left panel of Fig. 2 depicts disposition index at
baseline, independent of time before diabetes. Baseline
disposition index in women who developed diabetes at
any time during follow-up was only 41% of disposition
index in women who remained diabetes free (geometric
means [95% CIs] 384 [239–616] versus 931 [737–1,173];
P  0.002). Among women who developed diabetes, base-
line disposition index was lowest in those whom diabetes
developed within 5 years of the index pregnancy (261 [119–
569]) and intermediate in those whom diabetes developed
more than 5 years after the index pregnancy (615 [436–
886]). The right panel of Fig. 2 depicts the course of the
disposition index relative to the study end point of diabe-
tes or, in women who remained diabetes-free, completion
of follow-up. This format is important to allow visualiza-
tion of patterns of change with minimal impact of the
degree of deterioration at baseline. It is analogous to
assessing changes in disposition index by biological rather
than chronological age. The plot demonstrates that dispo-
sition index fell more rapidly in women who developed
diabetes (Fig. 2, right). Note that the number of people in
the “developed diabetes” group (Fig. 2, right) is relatively
small on the left of the graph because only a few individ-
uals who developed diabetes took the full 120–135 months
to do so.
DISCUSSION
This study provides the longest follow-up of which we are
aware that used detailed physiological measurements to
characterize the natural history of glucose regulation
following pregnancies complicated by GDM. Two general
types of physiological variables were associated with
development of type 2 diabetes: the degree of metabolic
deterioration at baseline (low insulin sensitivity and -cell
function, high glucose levels) and the rate of deterioration
thereafter (falling -cell compensation for insulin resis-
tance). To our knowledge, this is the ﬁrst demonstration
that both the degree of deterioration after pregnancy and
the rate of deterioration thereafter contribute to the risk of
diabetes. Our ﬁndings are consistent with the concept (4)
that GDM most commonly represents detection of a
chronic condition (i.e., low and falling -cell compensa-
tion for chronic insulin resistance) rather than develop-
ment of an acute condition (i.e., inability to compensate
for acquired insulin resistance) during pregnancy. That
concept is strongly supported by serial studies of insulin
resistance and -cell compensation in women who de-
velop GDM. Those studies reveal that the large majority of
the -cell defect observed during the third trimester is
present before (2) and after (3,4) pregnancy. Moreover,
TABLE 5
Multivariate assessment of signiﬁcant baseline and clinical vari-
ables during follow-up in relation to development of diabetes*
Variables
Adjusted HR
(95% CI)†
Adjusted
P value
Baseline‡
ivGTT DI§ 0.31 (0.17–0.54) 0.0001
Clamp 	Clrglu 0.50 (0.28–0.89) 0.018
oGTT total area 2.03 (1.21–3.39) 0.007
oGTT 30 	insulin§ 0.61 (0.37–1.02) 0.059
Follow-up
Weight change (per 5 kg) 1.67 (1.08–2.57) 0.021
Additional pregnancy (yes/no) 1.77 (0.92–3.44) 0.085
Progestin-only method (yes/no) 4.28 (0.90–20.4) 0.068
*Using multivariate Cox regression analysis where baseline variables
from Table 4 and follow-up clinical variables were included in the
model. †By Cox regression adjusting for other variables in the table;
for baseline variables, they were expressed per 1-SD unit increase;
for follow-up variables, they were expressed per 5-kg increase for
weight change and yes/no for additional pregnancy and progestin
contraception use. ‡Variables and units are deﬁned in Table 1.
§Variables were log transformed; SDs were calculated using log-
transformed data. All three follow-up variables were treated as
time-dependent variables in the Cox regression analysis.
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normal women during pregnancy (4), but they do so along
a sensitivity-section curve that is characterized by inap-
propriately low insulin secretion for any degree of insulin
resistance. Thus, from the physiological standpoint, it
appears that GDM is most often a chronic disease charac-
terized by insulin resistance and falling -cell compensa-
tion that is simply detected by routine glucose screening
during pregnancy.
In addition to the physiological variables, three clinical
variables provided information about the risk of diabetes
after GDM. Weight gain was the strongest, consistent with
prior clinical observations of shorter duration (10). Weight
gain is a known risk factor for diabetes; it can worsen
insulin resistance and -cell function as demonstrated
previously (11–13). Indeed, adjustment for weight gain
explained part of the association between falling -cell
compensation and diabetes risk in this study, suggesting
that the impact of falling compensation on diabetes risk
may have been mediated at least in part through weight
gain. Gain in body fat gave similar results to gain in weight,
suggesting that increased adiposity is the important com-
ponent of weight gain accentuating diabetes risk. Evi-
dence for association between diabetes and additional
pregnancy or progesterone-only contraception was statis-
tically marginal in this study, where only 20 women had
one or more additional pregnancies and 8 women used
progesterone-only contraception. However, the point esti-
mates for risk were substantial (1.77 for additional preg-
nancy and 4.28 for progestin-only contraception).
Moreover, we have previously found both events to be
signiﬁcantly associated with diabetes risk in a much larger
clinical cohort of women with prior GDM (10,14,15). The
present report adds validity to those prior ﬁndings and
demonstrates that the risks occur independently of base-
line glucose levels, insulin resistance, -cell function, and
weight gain. These three variables represent potentially
modiﬁable risk factors for diabetes after GDM.
Taken together, our ﬁndings in Hispanic women sug-
gest the following scenario for development of diabetes
after GDM. Chronic glucose intolerance is detected by
routine glucose screening during pregnancy. Women
who have that intolerance are at different stages in
progression toward diabetes, in part because they are
deteriorating at different rates. Women who are the
most insulin resistant also have the worst -cell func-
tion and highest glucose levels. They are closest to
diabetes and develop it soonest, as indicated by the Cox
regression analysis for baseline predictors of diabetes.
Faster deterioration is also associated with diabetes,
even after adjustment for where women are at baseline.
Gaining weight, becoming pregnant again, and using
progesterone-only contraception can accelerate devel-
opment of diabetes after GDM. Whether there is a
common mechanism underlying the effects of these
factors on -cell compensation remains to be deter-
mined. They are all modiﬁable and they represent, along
with amelioration of insulin resistance (16–17), poten-
tial clinical approaches to reducing diabetes risk after
GDM.
In summary, using the longest physiological follow-up of
women with prior GDM available to date, we found
important differences in both degrees and rates of meta-
bolic deterioration in our exclusively Hispanic cohort. The
differences, along with the occurrence of weight gain, an
additional pregnancy, and use of progestin-only contracep-
tion, had important associations with the risk of develop-
ing diabetes during more than a decade of follow-up. Our
ﬁndings provide three potentially modiﬁable clinical risk
factors for diabetes in this high-risk group. They also
suggest that genetic and environmental determinants of
rates of change in -cell compensation for chronic insulin
resistance should be an important focus of research to
understand the pathophysiology of both GDM and type 2
diabetes that so often follows it.
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